Chronic wounds, regardless of type, are associated with factors like increased levels of proteases (MMP-2 and MMP-9) and persistent overproduction of reactive oxygen species (ROS), which hinder healing. If an arterial ulcer reaches a point where these biochemical imbalances are present and the core circulatory problem is unresolved, it would then be considered a chronic wound.
Arterial ulcers are open sores that develop on the body due to poor blood circulation, specifically inadequate arterial blood flow. They are most commonly found on the lower extremities, such as the feet, ankles, and toes. These ulcers occur when arteries, which carry oxygen-rich blood away from the heart, become narrowed or blocked, usually due to atherosclerosis (hardening of the arteries). This reduction in blood supply deprives the tissues of necessary oxygen and nutrients, leading to tissue death and ulcer formation.
Arterial ulcers are open sores that develop on the body due to poor blood circulation, specifically inadequate arterial blood flow. They are most commonly found on the lower extremities, such as the feet, ankles, and toes. These ulcers occur when arteries, which carry oxygen-rich blood away from the heart, become narrowed or blocked, usually due to atherosclerosis (hardening of the arteries). This reduction in blood supply deprives the tissues of necessary oxygen and nutrients, leading to tissue death and ulcer formation.
The primary cause of arterial ulcers is peripheral artery disease (PAD), which is a buildup of plaque in the arteries that supply blood to the limbs. Risk factors for PAD and consequently arterial ulcers include:
Diagnosis typically involves a physical examination, assessment of pulses, and non-invasive vascular tests such as ankle-brachial index (ABI), Doppler ultrasound, or angiography to assess blood flow.
Treatment for arterial ulcers focuses on improving blood circulation and promoting wound healing. This often includes:
Unlike venous ulcers which often heal with compression, compression is generally contraindicated in arterial ulcers as it can further impede already compromised blood flow. The goal is to address the underlying circulatory problem to allow the ulcer to heal and prevent recurrence.
Regenerex is continuously evaluating new technologies to improve clinical and financial outcomes of products and programs.
If you have questions regarding arterial ulcers and how Regenerex technology can help the healing process, please contact us.
Regenerex Pharma, Inc. was incorporated in 2021. Regenerex has corporate offices located in Gordansville, Tennessee and a manufacturing facility in Memphis, Tennessee.